Myelofibrosis: Beyond Ruxolitinib | MedPage Today

Source link :

Up until fairly recently, ruxolitinib (Jakafi) was the only FDA-approved treatment for intermediate- and high-risk myelofibrosis, and thus has been the cornerstone of myelofibrosis treatment for more than a decade. However, in the last 5 years, three other JAK inhibitors have been approved — fedratinib (Inrebic) in 2019, pacritinib (Vonjo) in 2022, and momelotinib (Ojjaara) […]

Author : News Health

Publish date : 2024-06-07 19:22:22

Copyright for syndicated content belongs to the linked Source.